Related Experiment Video
Updated: Jun 27, 2025
06:13
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
1.1K
In type 2 diabetes, the effectiveness and side effects of GLP-1 RAs vary.
Clare O'Brien1, Sean F Dinneen1
1Centre for Diabetes, Endocrinology and Metabolism, Galway University Hospitals, Galway, Ireland (C.O., S.F.D.).
Annals of Internal Medicine
|May 6, 2024
Summary
Glucagon-like peptide-1 (GLP-1) receptor agonists effectively improve blood sugar control and reduce body weight in type 2 diabetes patients. This systematic review and network meta-analysis compared their effectiveness on key health markers.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) is a global health challenge requiring effective management strategies.
- Glucagon-like peptide-1 (GLP-1) receptor agonists represent a significant therapeutic class for T2DM.
- Comparative data on the effectiveness of various GLP-1 receptor agonists are crucial for clinical decision-making.
Purpose of the Study:
- To conduct a systematic review and network meta-analysis comparing the effectiveness of GLP-1 receptor agonists.
- To evaluate their impact on glycaemic control, body weight, and lipid profiles in patients with T2DM.
- To provide evidence-based insights for optimizing T2DM treatment.
Main Methods:
- Systematic literature search across major databases for relevant randomized controlled trials.
- Inclusion of studies comparing GLP-1 receptor agonists with placebo or other active treatments in T2DM patients.
- Network meta-analysis to synthesize direct and indirect evidence, assessing treatment efficacy and safety.
Main Results:
- GLP-1 receptor agonists demonstrated significant improvements in glycated hemoglobin (HbA1c) levels compared to placebo.
- Substantial reductions in body weight were observed across most GLP-1 receptor agonist classes.
- Variable effects on lipid profiles were noted, with some agents showing modest improvements in LDL cholesterol and triglycerides.
Conclusions:
- GLP-1 receptor agonists are highly effective for improving glycaemic control and promoting weight loss in T2DM.
- The choice of GLP-1 receptor agonist may depend on individual patient profiles and specific treatment goals.
- Further research is warranted to elucidate long-term cardiovascular outcomes and differential effects on lipid metabolism.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
318
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
01:23Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
173
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
173
01:06Oral Hypoglycemic Agents: Glinides
153
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
153
01:17Oral Hypoglycemic Agents: Sulfonylureas
205
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
205